dcSSc is an autoimmune disease in which dysregulated immune responses drive vascular endothelial injury and progressive tissue fibrosis. Autoimmunity is a near-universal feature. The interplay between genetic susceptibility factors, environmental exposures, and immune dysregulation contributes to disease initiation and progression, though no single genetic cause has been identified. No specific gene variants are included in the current data packet. The condition is not inherited in a Mendelian pattern and does not run in families in the conventional sense.

Diagnosis is based on established clinical classification criteria that incorporate the extent of skin thickening, specific autoantibody profiles, nailfold capillaroscopy findings, and the presence of characteristic organ involvement. Serological testing for autoantibodies — including anti-topoisomerase I (Scl-70) — supports diagnosis and informs prognosis. Pulmonary evaluation including high-resolution CT and pulmonary function testing is essential to characterize lung involvement. Echocardiography screens for pulmonary hypertension. Renal function monitoring is critical given the risk of renal crisis.

Treatment targets the specific organ manifestations of dcSSc and aims to slow progression and prevent complications. Tocilizumab, an interleukin-6 receptor inhibitor, received FDA approval in January 2025 for the treatment of adults with dcSSc and is used to address the inflammatory and fibrotic processes underlying the disease. Nintedanib, a tyrosine kinase inhibitor with orphan drug approval, is indicated for the treatment of systemic sclerosis-associated interstitial lung disease and slows the decline in lung function. Supportive measures include proton pump inhibitors for gastroesophageal reflux, antihypertensive agents for renal protection, and physical therapy for musculoskeletal complications. Immunosuppressive therapies are used for specific organ manifestations. Multiple investigational agents targeting fibrotic and immune pathways are under active evaluation in clinical trials.

dcSSc carries a more serious prognosis than the limited cutaneous subtype, driven by the risk of internal organ involvement. Pulmonary fibrosis, pulmonary arterial hypertension, and renal crisis are major determinants of long-term outcomes. Early identification of organ complications and timely treatment initiation are associated with better outcomes. The disease course varies considerably among individuals, with some experiencing rapid progression and others a more stable trajectory. Long-term monitoring for pulmonary, cardiac, and renal involvement is a key component of care.

The research landscape for dcSSc is active, with 18 registered clinical trials evaluating a range of therapeutic approaches. Investigational strategies include novel biologic agents, CAR-T cell therapies targeting B cells, and autologous stem cell transplantation for severe disease. The trial portfolio reflects broad interest in both immune-targeting and antifibrotic strategies. Published research includes a substantial volume of clinical trial publications, biomarker studies, and case reports, reflecting growing scientific focus on this condition. Ongoing work aims to identify predictive biomarkers, refine patient stratification, and expand the evidence base for approved and emerging therapies.